Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Anyang
Clinical trial register · China

Clinical Trials in Anyang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca12 Cancer Institute and Hospital, Chinese Academy of Medical Sciences5 Shanghai Pharmaceuticals Holding Co., Ltd5 Fudan University4 The First Affiliated Hospital of Zhengzhou University3
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Anyang

83 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Shanghai Henlius Biotech
Phase 2/3
1,438
Hefei, Beijing, Chongqing, Nanning, Zunyi, Shijiazhuang, Harbin, Anyang
2026-11-30
Recruiting
Novo Nordisk A/S
Phase 4
300
Fuyang, Beijing, Lanzhou, Huizhou, Shantou, Shijiazhuang, Anyang, Yichang
2026-10-12
Recruiting
AstraZeneca
Phase 3
950
Anyang, Beijing, Binzhou Shi, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2026-09-16
Recruiting
Capital Medical University
Phase 2
204
Anyang, Beijing, Huzhou, Jiuquan, Lishui, Shangqiu, Suzhou, Taizhou
2026-09-06
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
542
Anyang, Hangzhou, Shanghai
2026-09-01
Not yet open
Sun Yat-sen University
Phase 2
40
Guangzhou, Shijiazhuang, Anyang, Zhengzhou, Nanjing, Nanchang, Dalian, Chengdu
2026-08-28
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
84
Anyang, Beijing, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou
2026-07-05
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
127
Beijing, Lanzhou, Guangzhou, Anyang, Luoyang, Zhengzhou, Nanjing, Xuzhou
2026-07
Recruiting
AstraZeneca
Phase 2
84
Anyang, Beijing, Changsha, Chengdu, Chizhou, Haikou, Hefei, Hohhot
2026-06-24
Recruiting
The First Affiliated Hospital of Zhengzhou University
Not applicable
339
Anyang, Jiaozuo, Kaifeng, Luohe, Luoyang, Nanyang, Sanmenxia, Shangqiu
2026-06-20
Recruiting
AstraZeneca
Not applicable
1,000
Anyang, Baoding, Beijing, Cangzhou, Changzhi, Chengdu, Fuzhou, Guangzhou
2026-06-02
By invitation
The First Affiliated Hospital of Henan University of Science and Technology
Observational
12,000
Anyang, Luoyang, Nanyang
2026-05-15
Recruiting
Capital Medical University
Phase 3
348
Huaibei, Suzhou, Heyuan, Maoming, Qinhuangdao, Tangshan, Anyang, Hebi
2026-04-22
Not yet open
Southwest Hospital, China
Phase 3
488
Baise City, Guilin, Qiannan, Chengdu, Dali, Qujing, Ankang, Anyang
2026-03-25
Recruiting
Antengene Biologics Limited
Phase 1/2
132
Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Langfang, Shijiazhuang, Anyang
2026-02-27
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 2
110
Beijing, Anyang, Luoyang, Zhengzhou, Jinan, Suining
2026-02-26
Recruiting
Boehringer Ingelheim
Phase 3
1,325
Anyang, Baoji, Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu
2026-02-17
Recruiting
Eli Lilly and Company
Phase 3
800
Anyang, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang, Fuzhou Fujian
2025-12-22
Active, closed
Capital Medical University
Phase 3
692
Suzhou, Zhangzhou, Qinzhou, Langfang, Qinhuangdao, Tangshan, Harbin, Anyang
2025-12-05
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
180
Beijing, Fuzhou, Guangzhou, Harbin, Anyang, Zhengzhou, Xuzhou, Shenyang
2025-12-02
Active, closed
Dr. Willmar Schwabe GmbH & Co. KG
Phase 4
400
Anyang, Baotou, Beijing, Benxi, Chenzhou, Chifeng, Dalian, Harbin
2025-11-28
Recruiting
Kunming Pharmaceuticals, Inc.
Phase 2
300
Beijing, Shenzhen, Cangzhou, Hengshui, Daqing, Anyang, Nanyang, Xuzhou
2025-11-22
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Beijing, Chongqing, Fuzhou, Jiangmen, Anyang, Luoyang, Jingzhou, Wuhan
2025-11-05
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
414
Hefei, Fuzhou, Guangzhou, Meizhou, Nanning, Baoding, Harbin, Anyang
2025-09-02
Recruiting
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2/3
778
Anyang, Guangzhou, Jinan, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
2025-08-28
Recruiting
BeOne Medicines
Phase 3
351
Hefei, Beijing, Xiamen, Anyang, Zhengzhou, Nanjing, Ganzhou, Shenyang
2025-08-27
By invitation
Huabo Biopharm Co., Ltd.
Phase 2
60
Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin
2025-08-14
Not yet open
Fudan University
Phase 1/2
20
Anyang, Shanghai
2025-08-01
Recruiting
Fudan University
Phase 2
138
Fuzhou, Anyang, Jinan, Kunming, Shanghai
2025-08-01
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
216
Beijing, Dongguan, Guangdong, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha
2025-07-15
Recruiting
Du Zhenggui
Not applicable
337
Fuzhou, Guangzhou, Anyang, Zhengzhou, Changsha, Hohhot, Suzhou, Nanchang
2025-06-17
Recruiting
AstraZeneca
Phase 3
15,100
Anqing, Anyang, Baotou, Beijing, Bozhou, Changchun, Changde, Changsha
2025-06-04
Not yet open
Beijing 302 Hospital
Observational
2,000
Ankang, Anyang, Beihai, Beijing, Binzhou, Changzhi, Changzhou, Chengdu
2025-05-01
Recruiting
Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions
NCT07463664Chronic Total Occlusions of Coronary Arteries, Chronic Total Occlusion (CTO), Coronary Artery Disease (CAD)
The First Affiliated Hospital of Zhengzhou University
Not applicable
200
Beijing, Anyang, Jiaozuo, Jiyuan, Kaifeng, Luoyang, Nanyang, Pingdingshan
2025-04-28
Recruiting
Eli Lilly and Company
Phase 3
700
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Foshan, Guangzhou
2025-03-27
Recruiting
Daiichi Sankyo
Phase 3
510
Anyang, Beijing, Changchun, Changzhou, Chengdu, Fuzhou, Hangzhou, Harbin
2025-03-27
Recruiting
AstraZeneca
Phase 3
990
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-03-18
Recruiting
AstraZeneca
Phase 3
840
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou
2025-03-01
Recruiting
Fortvita Biologics (USA)Inc.
Phase 1
250
Hefei, Beijing, Fuzhou, Nanning, Harbin, Anyang, Luoyang, Zhengzhou
2025-01-10
Recruiting
Shenzhen Celconta Life Science Co., Ltd.
Phase 1
18
Anyang
2025-01
Not yet open
InnoBM Pharmaceuticals Co., Ltd.
Phase 3
228
Bengbu, Anyang, Zhengzhou, Nanjing, Lishui, Guangzhou, Lanzhou, Luoyang
2025-01
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
80
Beijing, Lanzhou, Guangzhou, Guigang, Nanning, Harbin, Anyang, Puyang
2024-11-06
Active, closed
Cola Ingestion for Esophageal Bolus Impaction
NCT06652620Esophageal Cancer
Fudan University
Not applicable
50
Xiamen, Anyang, Yangzhou, Jingdezhen, Shanghai
2024-11-01
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongguan
2024-08-22
Recruiting
JIANGSU SHENMING Medical Technology CO., Ltd
Not applicable
216
Hefei, Beijing, Nanning, Guiyang, Shijiazhuang, Anyang, Luoyang, Zhengzhou
2024-07-29
Recruiting
Jun Zhou
Phase 1
90
Fuzhou, Anyang, Jinan, Shanghai
2024-06-18
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin, Anyang, Zhengzhou
2024-06-04
Recruiting
The First Affiliated Hospital of Zhengzhou University
Observational
15,000
Anyang, Guangzhou, Hebi, Jiaozuo, Jiayuguan, Jinan, Jiyuan, Kaifeng
2024-06-03
Recruiting
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
NCT06421376Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy
DrugCardonilizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Anyang, Xinxiang, Beijing
2024-05-01
Not yet open
Fudan University
Phase 2
25
Anyang, Shanghai
2024-04-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
400
Beijing, Chongqing, Fuzhou, Anyang, Zhengzhou, Huai'an, Nanjing, Jinan
2024-03-30
Active, closed
TJ Biopharma Co., Ltd.
Phase 2/3
450
Anyang, Beijing, Bengbu, Binzhou, Changsha, Chongqing, Dongguan, Foshan
2024-03-28
Active, closed
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
Acerand Therapeutics (Shanghai) Limited
Phase 1/2
298
Chongqing, Fuzhou, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha, Jinan
2024-03-22
Recruiting
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
NCT06342167Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
57
Beijing, Fujian, Handan, Anyang, Xinxiang, Yinchuan, Feixian, Jining
2024-03-14
Recruiting
AstraZeneca
Phase 3
5,250
Anning, Anyang, Baotou, Beijing, Changsha, Changzhi, Chengdu, Chifeng
2024-02-21
Recruiting
Shenzhen Celconta Life Science Co., Ltd.
Phase 1
18
Anyang
2024-02-18
Recruiting
Hansoh BioMedical R&D Company
Phase 2
220
Hefei, Fujian, Fuzhou, Guangzhou, Harbin, Anyang, Luoyang, Nanyang
2024-02-06
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
68
Anyang, Bengbu, Changsha, Chengdu, Dongwan, Fuzhou, Guangzhou, Hangzhou
2024-01-11
Recruiting
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
400
Guangzhou, Shanghai, Anyang, Baoding, Beijing, Changchun, Changde, Changsha
2023-12-01
Recruiting
AstraZeneca
Phase 3
625
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2023-11-23
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
756
Harbin, Changsha, Nanchang, Shenyang, Jinan, Anyang, Beijing, Changchun
2023-11-15
Recruiting
LeonaBio
Phase 3
600
Anhui, Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqicun
2023-10-31
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
52
Hefei, Guangzhou, Liuzhou, Anyang, Luoyang, Shijiazhuang, Harbin, Xiangyang
2023-09-19
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2/3
254
Guangzhou, Liuzhou, Anyang, Luoyang, Shijiazhuang, Harbin, Wuhan, Nanjing
2023-09-08
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2/3
374
Fuzhou, Guangzhou, Guiyang, Anyang, Luoyang, Pingxiang, Changchun, Yinchuan
2023-04-24
Active, closed
Janssen Research & Development, LLC
Phase 3
12,523
Anyang, Baoji, Baotou, Beijing, Changchun, Changsha, Chengdu, Chenzhou
2023-02-15
Recruiting
AstraZeneca
Phase 3
3,527
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou
2022-12-13
Active, closed
A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion
NCT05615038Basilar Artery Occlusion, Endovascular Treatment
Beijing Tiantan Hospital
Not applicable
338
Hefei, Beijing, Anyang, Zhangzhou, Baotou
2022-11-07
Active, closed
Eli Lilly and Company
Phase 3
8,000
Anyang, Baoding, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang
2022-10-04
Active, closed
A Study of AL8326 in Non-Small Cell Lung Cancer
NCT06794957Non-small Cell Lung Cancer
DrugAL8326
Advenchen Laboratories, LLC
Phase 1
158
Bengbu, Hefei, Xuancheng, Anyang, Zhengzhou, Wuhan, Nanjing, Hangzhou
2022-05-19
Active, closed
AstraZeneca
Phase 3
1,051
Anyang, Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Hefei, Kunming
2022-02-07
Recruiting
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
NCT05245058HER2-positive Advanced Solid Tumors
DrugSPH5030
Shanghai Pharmaceuticals Holding Co., Ltd
Early Phase 1
150
Hefei, Beijing, Guangzhou, Nanning, Shijiazhuang, Harbin, Anyang, Zhengzhou
2022-01-21
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
22
Beijing, Anyang, Luoyang, Xuzhou, Taiyuan, Suining
2021-12-13
Active, closed
China National Biotec Group Company Limited
Phase 3
2,898
Anyang, Jiaozuo, Luohe, Xinxiang
2021-10-22
Active, closed
Zhigang Li
Phase 3
426
Shanghai, Anyang, Guangzhou, Hefei
2021-09-01
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
663
Bengbu, Hefei, Jiangmen, Shenzhen, Shijiazhuang, Anyang, Xinxiang, Zhengzhou
2021-05-12
Active, closed
AstraZeneca
Phase 3
640
Anyang, Beijing, Bengbu, Changsha, Changzhi, Chengdu, Chongqing, Fuzhou
2020-10-19
Active, closed
Hoffmann-La Roche
Phase 3
992
Anyang, Baoding, Beijing, Bengbu, Changchun, Changsha, Fujian, Guangzhou
2020-10-09
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 1/2
150
Anyang, Beijing, Changsha, Fuzhou, Hangzhou, Tianjin, Zhengzhou
2020-07-27
Recruiting
Chemoradiotherapy in Unresectable Esophageal Cancer
NCT04278287Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel, Unresectable Malignant Neoplasm
DrugsAlbumin-Bound Paclitaxel·Nab-paclitaxel·Cisplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
105
Anyang, Changsha, Nanjing, Beijing
2019-10-01
Active, closed
Henan Cancer Hospital
Phase 2
60
Anyang, Luoyang, Zhengzhou
2019-08-26
Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Not applicable
196
Anyang, Luoyang
2016-11
Recruiting
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
NCT04821778Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation, Targeted Therapy
DrugNimotuzumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
2,000
Anyang, Changsha, Nanjing, Beijing
2002-01-01
Rows per page Showing 1–83 of 83
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/anyang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 83 of those studies with a site in Anyang.

How many clinical trials are recruiting in Anyang?

55 of the 83 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 9 have not yet opened recruitment, 17 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Anyang), 83 studies
PhaseStudiesRecruitingShare
Phase 3291834.9%
Phase 2171120.5%
Not applicable9710.8%
Phase 1/29710.8%
Phase 1657.2%
Phase 2/3647.2%
Observational414.8%
Phase 4212.4%
Early Phase 1111.2%

Most active sponsors

Lead sponsors with the most studies (Anyang)
Lead sponsorStudiesRecruiting
AstraZeneca1210
Cancer Institute and Hospital, Chinese Academy of Medical Sciences55
Shanghai Pharmaceuticals Holding Co., Ltd55
Fudan University41
Capital Medical University32
Eli Lilly and Company32
The First Affiliated Hospital of Zhengzhou University33
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.21
MediLink Therapeutics (Suzhou) Co., Ltd.22
Nanjing Leads Biolabs Co.,Ltd22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.